Well, probably. Synairgen’s SNG001, Interferon beta
£21.29 per injection
Interferon beta
Naturally occurring antiviral protein
Cytokine
Interfere with viral replication
Induce fever and muscle pains (along with other cytokines)
Activate immune cells, natural killer cells and macrophages
Reduces protein synthesis in adjacent cells
Activates an enzyme to destroy RNA, further reducing protein synthesis
Stimulates many other interferon-stimulated genes
Stimulates infected cells into apoptosis
Key component of human immune defence against viral infection
Phase 2 study
Inhaled interferon beta
Gives high local concentrations
Placebo controlled
n = 101 hospitalised patients
All patients tested positive for SARS-CoV-2
9 UK hospitals
Diabetics
Treatment group = 9
Placebo group = 3
Cardiovascular disease
Treatment group = 5
Placebo group = 8
Now recruiting patients ill with COVID-19 in the community
Results
79% reduction in risk of developing severe disease
Requiring ventilation or resulting in death
During the treatment period
Day one to day 16
This difference was also noted to day 28
Patients who received SNG001 were more than twice as likely to recover
Defined as ‘no limitation of activities’ or ‘no clinical or virological evidence of infection’
Measure of breathlessness, markedly reduced
In patients with more severe disease at time of admission
SNG001 increased the likelihood of hospital discharge during the study
Six days versus nine days for those receiving placebo (not significant difference)
More than twice as likely to have recovered by the end of the treatment period (strong
trend)
Safety
6% died after being randomised to placebo
No deaths in the SNG001 group
Professor Tom Wilkinson
Professor of Respiratory Medicine, University of Southampton
Trial chief investigator
Huge potential
To be able to restore the lung’s immune response
Enhancing protection
Accelerating recovery
Countering the impact of SARS-CoV-2 virus
Professor Stephen Holgate
Medical Research Council
Clinical Professor of Immunopharmacology at the University of Southampton
Restores the lung’s ability to neutralise the virus
or any mutation of the virus
or co-infection with another respiratory virus such as influenza
Relationship with dexamethasone and remdesivir
Study did not include patients requiring ventilatory support
If you would like to donate to this educational project, please use the following link, thank you,
